Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WRITE: Ribavirin Dosages and Durations in HCV Genotypes 2 and 3
NCT01380938Phase 3Completed
- Sponsor
- Casa Sollievo della Sofferenza
- Start
- Dec 2018
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribavirin in hepatitis C (HCV) (3 arms), sponsored by Casa Sollievo della Sofferenza. Primary endpoint: Sustained Virological Response. Started Dec 2018; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01380938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380938.